US Genomics last week said it has formed a partnership with the Lahey Clinic to develop microRNA-based diagnostics for urologic cancers using the company’s molecular-detection and -analysis technologies.
The deal is US Genomics’ second in the miRNA space, coming about five months after it struck a similar arrangement with Rosetta Genomics to co-develop an miRNA-based lung cancer diagnostic (see
RNAi News, 5/25/2006).
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
